How an expecting mother’s booster shots can protect her newborn from a host of diseases

Vaccines recommended during pregnancy — including Tdap, COVID-19 boosters, influenza, and the RSV vaccine (Abrysvo) — protect newborns by transferring matern...

What Happened

Vaccines recommended during pregnancy — including Tdap, COVID-19 boosters, influenza, and the RSV vaccine (Abrysvo) — protect newborns by transferring maternal antibodies across the placenta and through breast milk, a mechanism called passive immunity.
Maternal immunization (MI) is a clinically validated strategy to protect infants in the first weeks and months of life, before they are old enough to be directly vaccinated.
Whooping cough (pertussis), RSV (Respiratory Syncytial Virus), influenza, and tetanus remain significant causes of infant mortality globally; maternal vaccines address all four.
India's Universal Immunization Programme (UIP) currently covers only tetanus toxoid/Td vaccine for pregnant women; Tdap is not yet included in India's national schedule, though global evidence strongly supports its inclusion.
Research suggests that expanding maternal immunization in India to include influenza and RSV vaccines could prevent over 10,000 newborn deaths annually.

Static Topic Bridges

Maternal Immunization and Passive Immunity

Maternal immunization refers to vaccinating a pregnant woman to protect her unborn child or newborn. The mechanism operates through two routes: (1) Transplacental transfer — IgG antibodies produced by the mother's immune system cross the placental barrier and enter fetal circulation, providing protection at birth; (2) Breastfeeding — Secretory IgA antibodies in breast milk provide mucosal immunity to the newborn's gastrointestinal and respiratory tracts. This is "passive immunity" because the infant receives ready-made antibodies rather than generating its own immune response.

IgG is the only antibody class that crosses the placenta (via the neonatal Fc receptor, FcRn)
The transfer is most efficient in the third trimester; premature infants receive fewer maternal antibodies
Passive immunity from maternal vaccination typically lasts 3–6 months in the infant — the critical "immunity gap" window before the infant's own primary vaccination series takes effect
IgA in breast milk protects mucosal surfaces (gut, respiratory tract); particularly important for gastrointestinal and respiratory infections

Connection to this news: Understanding IgG transplacental transfer explains why timing of maternal vaccination matters — third trimester vaccination maximises antibody levels transferred to the fetus before birth.

Tdap Vaccine

Tdap is a combination vaccine protecting against Tetanus, Diphtheria, and acellular Pertussis (whooping cough). "Acellular" pertussis means only specific purified proteins of Bordetella pertussis are used (not killed whole cells), resulting in fewer side effects. Tdap differs from DTP (used in childhood immunisation) in that it contains lower antigen doses of diphtheria and pertussis, suitable for adolescents and adults.

Recommended timing in pregnancy: 27–36 weeks of gestation (third trimester); ideally around 28 weeks to maximise transplacental antibody transfer
Protects newborns against pertussis before they receive their own DTP vaccines (first dose given at 6 weeks in India)
Pertussis (whooping cough) is most dangerous in infants under 3 months — case fatality rate in this age group is significantly higher than in older children
Tdap is WHO-recommended for all pregnant women in every pregnancy
India's UIP currently uses Td (Tetanus-Diphtheria, without pertussis component) for pregnant women — Tdap is available in private sector but not on the national schedule

Connection to this news: Tdap during pregnancy is the single most evidence-backed maternal vaccine; its absence from India's national schedule represents a policy gap with significant public health implications.

RSV Vaccine (Abrysvo)

Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infection in infants and young children worldwide, responsible for approximately 100,000 child deaths annually. RSV causes bronchiolitis and pneumonia. There is no specific antiviral treatment; management is largely supportive.

Abrysvo (by Pfizer): First approved maternal RSV vaccine; FDA approved in August 2023; given as a single dose between 32–36 weeks of gestation
Mechanism: Bivalent RSV prefusion F protein vaccine; induces maternal antibodies (anti-RSV F IgG) that cross the placenta
Clinical trial efficacy: Reduced risk of severe RSV-associated lower respiratory illness in infants by approximately 82% within 90 days of birth; reduced hospitalisation risk by ~68%
A separate product, Nirsevimab (Beyfortus by AstraZeneca/Sanofi), is a monoclonal antibody given directly to the infant (not a vaccine) — an alternative prophylactic strategy
WHO prequalification for Abrysvo is under review; Indian regulatory approval status is pending

Connection to this news: The RSV vaccine represents the newest addition to the maternal immunization toolkit; its third-trimester timing is compatible with Tdap and influenza vaccines, enabling co-administration.

India's Universal Immunization Programme (UIP)

The Universal Immunization Programme is one of the largest public health programmes in the world, providing free vaccines to children and pregnant women across India. It was launched in 1978 (as Expanded Programme on Immunization) and became Universal (UIP) in 1985. It is implemented by the Ministry of Health and Family Welfare.

Vaccines for pregnant women under UIP: Tetanus Toxoid (TT) / Td vaccine — two doses in first pregnancy, one booster in subsequent pregnancies
Vaccines for infants/children under UIP: BCG, OPV, Pentavalent (DTP + Hib + HepB), PCV, IPV, MR, JE, Rotavirus, Td (booster at 5 and 10 years)
Mission Indradhanush (2014): Intensified drive to increase full immunization coverage; targets districts with low coverage
India's full immunization coverage: approximately 76–90% depending on the state and survey
National Immunization Schedule (NIS) does not currently include Tdap, influenza, or RSV vaccine for pregnant women
COVID-19 vaccine was recommended during pregnancy from 2021 onward (Covishield, Covaxin after first trimester)

Connection to this news: The gap between India's UIP (Td only for pregnant women) and the global evidence base (Tdap + influenza + RSV) highlights the policy reform needed to reduce preventable neonatal and infant deaths.

Immunological Basis of Newborn Vulnerability

Newborns are immunologically naive — their adaptive immune system (T cells, B cells, antibody production) is functional but inexperienced. They rely entirely on: (1) innate immunity (physical barriers, phagocytes), (2) maternal antibodies (passive immunity). The "immunity gap" between birth and completion of the primary vaccination series (at 14 weeks in India's schedule) is the highest-risk window for vaccine-preventable infections.

Pertussis: Most dangerous in infants under 3 months; 90% of pertussis deaths occur in this age group globally
RSV: Peak severity in infants under 6 months; premature infants are at highest risk
Influenza: Infants under 6 months cannot receive influenza vaccines; maternal immunization is the only protective strategy
Tetanus neonatorum: Caused by contaminated cord cutting; TT/Td maternal vaccination nearly eliminates this risk

Connection to this news: The biological vulnerability of newborns — and the specific "immunity gap" window — is the scientific rationale for all maternal immunization strategies discussed in the article.

Key Facts & Data

Tdap recommended timing: 27–36 weeks gestation (third trimester)
Antibody class that crosses placenta: IgG (via FcRn receptor)
Antibody in breast milk: Secretory IgA
RSV vaccine (Abrysvo): FDA approved August 2023; given at 32–36 weeks gestation
Abrysvo efficacy: ~82% reduction in severe RSV lower respiratory illness within 90 days of birth
RSV hospitalisation risk reduction: ~68% within 3 months of birth
Annual RSV child deaths globally: ~100,000
India's UIP maternal vaccine: Td (Tetanus-Diphtheria) only — two doses first pregnancy, one booster thereafter
Tdap status in India: Available privately, not in national schedule
MI potential in India: Could prevent >10,000 newborn deaths/year if RSV + influenza vaccines added
DTP first dose in India's NIS: 6 weeks of age
Mission Indradhanush launched: 2014; intensifies routine immunization
UIP launched: 1978 (as EPI); became Universal in 1985
Pertussis deaths in infants <3 months: >90% of all pertussis deaths globally